Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.transci.2021.103158 http://scihub22266oqcxt.onion/10.1016/j.transci.2021.103158 33994106!8106203!33994106     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transfus+Apher+Sci 2021 ; 60 (4): 103158 Nephropedia Template TP {{tp|p=33994106|t=2021. Efficacy of convalescent plasma therapy in severe COVID-19 patients |pdf=|usr=}}{{33994106}} gab.com Text Efficacy of convalescent plasma therapy in severe COVID-19 patients JO: Transfus Apher Sci http://www.kidney.de/pget.php?&tw=1&pmid=33994106 #FOAvip INTRODUCTION: The use of convalescent plasma (CP) transfusions is very valuable in the current COVID-19 outbreak, given that there are no specific preventive and therapeutic options. MATERIALS AND METHODS: 50 patients with severe COVID-19 disease treated with convalescent plasma transfusion were included in the study. The efficacy of CP and in which situations it was effective were investigated. CONCLUSION: 80 % of the patients recovered, and 20 % died in our study. The mean age of the patients who died was found to be higher than the patients who recovered. CRP, ferritin, D-dimer, neutrophil, MPV, and NLR counts were found to be higher, and lymphocyte and platelet counts were lower in the deceased group after CP. It was determined that patients who received CP within the first five days were hospitalized for a shorter period. DISCUSSION: Administration of CP transfusion within the first five days in severe COVID-19 patients has been shown to reduce hospital stay length. Twit Text FOAVip Efficacy of convalescent plasma therapy in severe COVID-19 patients ????Transfus Apher Sci http://www.kidney.de/pget.php?&tw=1&pmid=33994106 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33994106 #FOAvip English Wikipedia <ref>{{Cite pmid|33994106}}</ref> Efficacy of convalescent plasma therapy in severe COVID-19 patients #MMPMID33994106 Akay Cizmecioglu H; Goktepe MH; Demircioglu S; Tekinalp A; Cizmecioglu A; Tuna AK; Ozer H Transfus Apher Sci 2021[Aug]; 60 (4): 103158 PMID33994106show ga INTRODUCTION: The use of convalescent plasma (CP) transfusions is very valuable in the current COVID-19 outbreak, given that there are no specific preventive and therapeutic options. MATERIALS AND METHODS: 50 patients with severe COVID-19 disease treated with convalescent plasma transfusion were included in the study. The efficacy of CP and in which situations it was effective were investigated. CONCLUSION: 80 % of the patients recovered, and 20 % died in our study. The mean age of the patients who died was found to be higher than the patients who recovered. CRP, ferritin, D-dimer, neutrophil, MPV, and NLR counts were found to be higher, and lymphocyte and platelet counts were lower in the deceased group after CP. It was determined that patients who received CP within the first five days were hospitalized for a shorter period. DISCUSSION: Administration of CP transfusion within the first five days in severe COVID-19 patients has been shown to reduce hospital stay length. |*SARS-CoV-2/immunology[MESH] |Age Factors[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Blood Cell Count[MESH] |C-Reactive Protein/analysis[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/blood/mortality/*therapy[MESH] |Female[MESH] |Ferritins/blood[MESH] |Fibrin Fibrinogen Degradation Products/analysis[MESH] |Hospital Mortality[MESH] |Hospitals, University[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Length of Stay/statistics & numerical data[MESH] |Male[MESH] |Middle Aged[MESH]Efficacy of convalescent plasma therapy in severe COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing